comparemela.com

Latest Breaking News On - Biopharmaceutical contract - Page 5 : comparemela.com

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at.

United statesComunidad autonoma de catalunaKerry wycisloRobin deterdingBoehringer ingelheimSusanne stowasserBoehringer ingelheim pharmaceuticalsBoehringer ingelheim pharmaceuticals incEuropean respiratory society international congressDrug administrationInternational congressEuropean respiratory societyHuman pharma communicationsAnimal healthEuropean medicines agencyCorporate affairs

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

More than half of patients treated with SPEVIGO® (spesolimab-sbzo) injection, for intravenous use showed no visible pustules one week after receiv.

New yorkUnited statesPrnewswire boehringer ingelheimThomas seckCarinne brouillonMark lebwohlChris wahlersBoehringer ingelheim pharmaceuticalsEricj waldman department of dermatologyRegulatory affairsDrug administrationBoehringer ingelheimIcahn school of medicine at mount sinaiAnimal healthClinical therapeuticsIcahn school

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

/PRNewswire/ Boehringer Ingelheim announced today the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for.

New yorkUnited statesPrnewswire boehringer ingelheimThomas seckCarinne brouillonMark lebwohlChris wahlersBoehringer ingelheim pharmaceuticalsEricj waldman department of dermatologyRegulatory affairsDrug administrationBoehringer ingelheimIcahn school of medicine at mount sinaiAnimal healthClinical therapeuticsIcahn school

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

/PRNewswire/ Boehringer Ingelheim announced today the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for.

New yorkUnited statesPrnewswire boehringer ingelheimThomas seckCarinne brouillonMark lebwohlChris wahlersBoehringer ingelheim pharmaceuticalsEricj waldman department of dermatologyRegulatory affairsDrug administrationBoehringer ingelheimIcahn school of medicine at mount sinaiAnimal healthClinical therapeuticsIcahn school

Evotec SE: Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance

HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical

Volker braunMichel pairetWerner lanthalerGabriele hansenBoehringer ingelheimEvotec se frankfurt stock exchangeBoehringer ingelheim venture fundEu innovative medicines initiativeHead of global corporate communications marketingAnimal healthFrankfurt stock exchangeAntimicrobial resistanceAurobac therapeuticsCompanion diagnosticsMedicines initiativeHuman pharma

vimarsana © 2020. All Rights Reserved.